🇺🇸 Granulocyte Colony Stimulating Factor in United States

4,736 US adverse-event reports

Marketing authorisation

FDA

• Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 20 April 2025 – 20 April 2026
• Total reports: 4,736

Most-reported reactions

1. Febrile Neutropenia — 870 reports (18.37%)
2. Neutropenia — 647 reports (13.66%)
3. Off Label Use — 548 reports (11.57%)
4. Pyrexia — 451 reports (9.52%)
5. Thrombocytopenia — 441 reports (9.31%)
6. Anaemia — 397 reports (8.38%)
7. Diarrhoea — 350 reports (7.39%)
8. Mucosal Inflammation — 347 reports (7.33%)
9. Pneumonia — 347 reports (7.33%)
10. Myelosuppression — 338 reports (7.14%)

Source database →

Frequently asked questions

Is Granulocyte Colony Stimulating Factor approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for Granulocyte Colony Stimulating Factor in United States?

Emory University is the originator. The local marketing authorisation holder may differ — check the official source linked above.